Catridecacog

Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU^[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.^[2] It was brought to market by Novo Nordisk.^[1]

Catridecacog

Clinical data
Trade names	Tretten, NovoThirteen
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN US DailyMed: Catridecacog
Pregnancy category	AU: B2
Routes of administration	Injection
ATC code	B02BD11 (WHO)
Legal status
Legal status	AU: Unscheduled US: ℞-only EU: Rx-only
Identifiers
CAS Number	606138-08-3
DrugBank	DB09310
ChemSpider	none
UNII	NU23Q531G1
KEGG	D10532
ChEMBL	ChEMBL2108282